This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.
This content is restricted to subscribers
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Ohio
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
Department of Quantitative Health Sciences, Cleveland Clinic, Ohio
Neurological Institute, Center for Outcomes Research & Evaluation, Cleveland Clinic, Ohio
Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Ohio
Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, EC-10 Cleveland Clinic, Ohio
References (44)
Reuben C, Elgaddal N, Black LI. Sleep Medication Use in Adults Aged 18 and Over: United States, 2020. NCHS Data Brief. 2023;(462):1–8. Accessed February 16, 2023. https://www.cdc.gov/nchs/data/databriefs/db462.pdf
Brandt J, Leong C. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D. 2017;17(4):493–507. PubMedCrossRef
Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952–1960. PubMedCrossRef
Treves N, Perlman A, Kolenberg Geron L, et al. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. Age Ageing. 2018;47(2):201–208. PubMedCrossRef
Schifano F, Chiappini S, Corkery JM, et al. An insight into Z-drug abuse and dependence: an examination of reports to the European Medicines Agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol. 2019;22(4):270–277. PubMedCrossRef
Szmulewicz A, Bateman BT, Levin R, et al. The risk of overdose with concomitant use of Z-drugs and prescription opioids: a population-based cohort study. Am J Psychiatry. 2021;178(7):643–650. PubMedCrossRef
Scharner V, Hasieber L, Sönnichsen A, et al. Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2022;22(1):87. PubMedCrossRef
Tubbs AS, Ghani SB, Naps M, et al. Past-year use or misuse of an opioid is associated with use of a sedative-hypnotic medication: a US National Survey on Drug Use and Health (NSDUH) study. J Clin Sleep Med. 2022;18(3):809–816. PubMedCrossRef
Tardelli VS, Bianco MCM, Prakash R, et al. Overdose deaths involving non-BZD hypnotic/sedatives in the USA: trends analyses. Lancet Reg Health Am. 2022;10:100190. PubMedCrossRef
Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55–64. PubMedCrossRef
Choudhry AA, Shahzeen F, Choudhry SA, et al. Impact of COVID-19 infection on quality of sleep. Cureus. 2021;13(9):e18182. PubMedCrossRef
Murphy MT, Latif U. Pain during COVID-19: a comprehensive review and guide for the interventionalist. Pain Pract. 2021;21(1):132–143. PubMedCrossRef
Currie JM, Schnell MK, Schwandt H, et al. Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic. JAMA Netw Open. 2021;4(4):e216147. PubMedCrossRef
Anderson KE, Basting JL, Gifeisman RI, et al. High prescribing and state-level variation in Z-drug use among Medicare patients. medRxiv. Preprint posted online May 10, 2022. doi:10.1101/2022.05.10.22274909 >
Cadogan CA, Ryan C, Cahir C, et al. Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015. Br J Clin Pharmacol. 2018;84(6):1354–1363. PubMedCrossRef
Kim HM, Gerlach LB, Van T, et al. Predictors of long-term and high-dose use of zolpidem in veterans. J Clin Psychiatry. 2019;80(2):18m12149. PubMedCrossRef
Esechie A, Kuo Y-F, Goodwin JS, et al. Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare part D beneficiaries from 2013 to 2018: a retrospective study. BMJ Open. 2021;11(11):e053487. PubMedCrossRef
Mokhar A, Tillenburg N, Dirmaier J, et al. Potentially inappropriate use of benzodiazepines and Z-drugs in the older population-analysis of associations between long-term use and patient-related factors. PeerJ. 2018;6(5):e4614. PubMedCrossRef
Woods A, Begum M, Gonzalez-Chica D, et al. Long-term benzodiazepines and z-drug prescribing in Australian general practice between 2011 and 2018: A national study. Pharmacol Res Perspect. 2022;10(1):e00896. PubMedCrossRef
Landolt S, Rosemann T, Blozik E, et al. Benzodiazepine and Z-drug use in Switzerland: prevalence, prescription patterns and association with adverse healthcare outcomes. Neuropsychiatr Dis Treat. 2021;17:1021–1034. PubMedCrossRef
Gerlach LB, Maust DT, Leong SH, et al. Factors associated with long-term benzodiazepine use among older adults. JAMA Intern Med. 2018;178(11):1560–1562. PubMedCrossRef
Soyombo S, Stanbrook R, Aujla H, et al. Socioeconomic status and benzodiazepine and Z-drug prescribing: a cross-sectional study of practice-level data in England. Fam Pract. 2020;37(2):194–199. PubMedCrossRef
Alimoradi Z, Gozal D, Tsang HWH, et al. Gender-specific estimates of sleep problems during the COVID-19 pandemic: systematic review and meta-analysis. J Sleep Res. 2022;31(1):e13432. PubMedCrossRef
Salfi F, Lauriola M, Amicucci G, et al. Gender-related time course of sleep disturbances and psychological symptoms during the COVID-19 lockdown: a longitudinal study on the Italian population. Neurobiol Stress. 2020;13:100259. PubMedCrossRef
Tardelli VS, Fidalgo TM, Martins SS. How do medical and non-medical use of Z-drugs relate to psychological distress and the use of other depressant drugs? Addict Behav. 2021;112:106606. PubMedCrossRef
Nunes J, Jean-Louis G, Zizi F, et al. Sleep duration among black and white Americans: results of the National Health Interview Survey. J Natl Med Assoc. 2008;100(3):317–322. PubMedCrossRef
Cheng P, Cuellar R, Johnson DA, et al. Racial discrimination as a mediator of racial disparities in insomnia disorder. Sleep Health. 2020;6(5):543–549. PubMedCrossRef
Amyx M, Xiong X, Xie Y, et al. Racial/ethnic differences in sleep disorders and reporting of trouble sleeping among women of childbearing age in the United States. Matern Child Health J. 2017;21(2):306–314. PubMedCrossRef
Hoffman KM, Trawalter S, Axt JR, et al. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. Proc Natl Acad Sci U S A. 2016;113(16):4296–4301. PubMedCrossRef
Kaufmann CN, Spira AP, Alexander GC, et al. Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010. Pharmacoepidemiol Drug Saf. 2016;25(6):637–645. PubMedCrossRef
Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169–1173. PubMedCrossRef
Schepis TS, Teter CJ, Simoni-Wastila L, et al. Prescription tranquilizer/sedative misuse prevalence and correlates across age cohorts in the US. Addict Behav. 2018;87:24–32. PubMedCrossRef
Lebrasseur A, Fortin-Bédard N, Lettre J, et al. Impact of the COVID-19 pandemic on older adults: rapid review. 2021;4(2):e26474.
De Pue S, Gillebert C, Dierckx E, et al. The impact of the COVID-19 pandemic on wellbeing and cognitive functioning of older adults. Sci Rep. 2021;11(1):4636. PubMedCrossRef
Morin CM, Bjorvatn B, Chung F, et al. Insomnia, anxiety, and depression during the COVID-19 pandemic: an international collaborative study. Sleep Med. 2021;87:38–45. PubMedCrossRef
Kalmbach DA, Anderson JR, Drake CL. The impact of stress on sleep: pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. J Sleep Res. 2018;27(6):e12710. PubMedCrossRef
Linnet K, Thorsteinsdottir HS, Sigurdsson JA, et al. Co-prescribing of opioids and benzodiazepines/Z-drugs associated with all-cause mortality: A population-based longitudinal study in primary care with weak opioids most commonly prescribed. Front Pharmacol. 2022;13:932380. PubMedCrossRef
Doherty AJ, Boland P, Reed J, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 2020;4(3):bjgpopen20X101096. PubMedCrossRef
Treating Substance Use Disorder in Older Adults: Updated 2020. Substance Abuse and Mental Health Services Administration; 2020. Accessed August 28, 2022. https://pubmed.ncbi.nlm.nih.gov/34106564/
Conti EC, Stanley MA, Amspoker AB, et al. Sedative-hypnotic use among older adults participating in anxiety research. Int J Aging Hum Dev. 2017;85(1):3–17. PubMedCrossRef
Mason M, Soliman R, Kim HS, et al. Disparities by sex and race and ethnicity in death rates due to opioid overdose among adults 55 years or older, 1999 to 2019. JAMA Netw Open. 2022;5(1):e2142982. PubMedCrossRef
Soni A, Thiyagarajan A, Reeve J. Feasibility and effectiveness of deprescribing benzodiazepines and Z-drugs: systematic review and meta-analysis. Addiction. 2023;118(1):7–16. PubMedCrossRef
Rasmussen AF, Poulsen SS, Oldenburg LIK, et al. The barriers and facilitators of different stakeholders when deprescribing benzodiazepine receptor agonists in older patients—a systematic review. Metabolites. 2021;11(4):254. PubMedCrossRef